Results from a prespecified exploratory analysis of the FLAURA2 Phase III trial showed AstraZeneca s Tagrisso with the addition of chemotherapy demonstrated a 42% improvement in central.
Treating patients with Tagrisso, a tyrosine kinase inhibitor, plus chemotherapy reduced the progression risk of disease of the central nervous system in patients with EGFR-positive non-small cell lung cancer.
Despite a high-profile clinical disappointment, the TIGIT immune checkpoint remains an important target for anticancer therapy, with research programs testing novel agents moving forward in non–small cell lung cancer and a range of other tumor types.
Antibody-drug conjugate shows impressive activity in patients with non-small cell lung cancer with mutation miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Antibody-drug conjugate shows impressive activity in patients with non-small cell lung cancer with mutation in HER2 gene pressreleasepoint.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressreleasepoint.com Daily Mail and Mail on Sunday newspapers.